Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02140151
Previous Study | Return to List | Next Study

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (PREVENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02140151
Recruitment Status : Completed
First Posted : May 16, 2014
Last Update Posted : August 25, 2022
Sponsor:
Information provided by (Responsible Party):
Southern California Desert Retina Consultants, MC

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This study will determine whether quarterly injections of Ranibizumab may prevent eyes with dry age-related macular degeneration from progressing to wet age-related macular degeneration (AMD).

Condition or disease Intervention/treatment Phase
Age-related Macular Degeneration Drug: Ranibizumab 0.5mg Phase 1 Phase 2

Detailed Description:

This is a multicenter, prospectively randomized, masked and controlled, interventional investigator sponsored phase I/II study of subjects with high-risk nonexudative age-related macular degeneration (AMD) treated with intravitreal ranibizumab quarterly for prophylaxis of conversion to exudative age-related macular degeneration.

The objective of this study is to investigate the safety and efficacy of prophylactic anti-vascular endothelial growth factor (VEGF) therapy with ranibizumab to prevent the development of exudative AMD in eyes with high-risk nonexudative AMD. In addition, baseline characteristics of high-risk eyes (fundus features, optical coherence tomography (OCT) parameters and genetic profile) will be evaluated to determine their predictive value in conversion to exudative AMD. The effect of ranibizumab on the atrophic component of AMD will also be monitored.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Eyes With Nonexudative AMD Trial: A Multicenter, Prospectively Randomized, Masked and Controlled, Interventional Investigator Sponsored Phase I/II Study
Actual Study Start Date : September 17, 2014
Actual Primary Completion Date : July 9, 2020
Actual Study Completion Date : July 9, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
No Intervention: Sham
Sham Injection
Active Comparator: Quarterly Ranibizumab 0.5mg
Quarterly intravitreal injection of 0.5mg ranibizumab
 Drug: Ranibizumab 0.5mg
Other Name: Lucentis


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Development of exudative AMD [ Time Frame: 2 years ]
    Development of choroidal neovascularization (conversion) defined by the presence of leakage on fluorescein angiography (FA) and fluid within or below the retina or below the retinal pigment epithelium seen on spectral-domain optical coherence tomography (SD-OCT)


Secondary Outcome Measures :
  1. Vision change [ Time Frame: 2 years ]
    Change in best-corrected visual acuity (BCVA) from baseline at 12 and 24 months

  2. Vision loss [ Time Frame: 2 years ]
    Proportion of eyes losing < 5, 10, and 15 letters on EDTRS chart at 12 and 24 months

  3. Number of injections [ Time Frame: 2 years ]
    Number of injections required in eyes that convert from dry to wet AMD during the study period

  4. Baseline predictive factors [ Time Frame: 2 years ]
    Baseline demographic, genetic and ocular characteristics predictive of development of wet AMD

  5. Development of geographic atrophy (GA) [ Time Frame: 2 years ]
    Development of geographic atrophy (GA) as detected by fundus photography (FP) and/or fundus autofluorescence (AF).

  6. Ocular adverse events [ Time Frame: 2 years ]
    Incidence and severity of ocular adverse events, as identified by eye examination and imaging

  7. Systemic adverse events [ Time Frame: 2 years ]
    Incidence and severity of other adverse events, as identified by physical examination or subject reporting.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult over 50 years old
  • Able to sign informed consent and comply with the study protocol for the duration of two years
  • Nonexudative age-related macular degeneration (AMD) in one eye (study eye)
  • History of exudative AMD in one eye only (fellow eye) diagnosed within 5 years of study enrollment

Exclusion Criteria:

  • Participation in another simultaneous medical investigation or clinical trial
  • Patient is pregnant, lactating, or premenopausal and not using adequate contraception
  • Known serious allergies to ranibizumab, fluorescein dye, drugs for pupillary dilation, topical anesthetic, sterilizing solution (e.g. Betadine solution)
  • Presence of ocular conditions with increased risk of choroidal neovascularization (CNVM) or pigment epithelial detachment (PED), including presumed ocular histoplasmosis syndrome (POHS), traumatic choroidal rupture, angioid streaks, pathologic myopia (spherical equivalent of ≥ -8 diopters or axial length of ≥ 25 mm), multifocal choroiditis, macular choroidal nevus, polypoidal choroidal vasculopathy (PCV), idiopathic central serous chorioretinopathy (ICSC), etc.
  • History of vitrectomy in the study eye
  • History of cataract surgery within 3 months of enrollment
  • History of yttrium aluminum garnet (YAG) capsulotomy within 1 month of enrollment
  • History of intraocular or periocular corticosteroid therapy within the past 90 days
  • History of therapeutic radiation in the region of the study eye.
  • Presence of media opacity that would preclude adequate examination and/or imaging
  • Concurrent macular conditions that would affect the study parameters (epiretinal membrane, macular hole, macular edema) or require treatment within the duration of the study
  • Any progressive ocular condition (uncontrolled glaucoma, diabetic retinopathy, uveitis) that may affect the visual acuity for the duration of the study
  • Active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at enrollment
  • Presence of any advanced systemic condition that may hinder the patients participation and completion of the study
  • Concurrent use of systemic anti-VEGF therapy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02140151


Locations
Layout table for location information
United States, California
Northern California Retina Vitreous Associates
Mountain View, California, United States, 94040
Southern California Desert Retina Consultants
Palm Desert, California, United States, 92211
United States, Maryland
Elman Retina
Baltimore, Maryland, United States, 21237
United States, South Dakota
Black Hills Regional Eye Institute
Rapid City, South Dakota, United States, 57701
Sponsors and Collaborators
Southern California Desert Retina Consultants, MC
Investigators
Layout table for investigator information
Principal Investigator: Maziar Lalezary, MD Southern California Desert Retina Consultants
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Southern California Desert Retina Consultants, MC
ClinicalTrials.gov Identifier: NCT02140151    
Other Study ID Numbers: ML29258
First Posted: May 16, 2014    Key Record Dates
Last Update Posted: August 25, 2022
Last Verified: August 2022
Keywords provided by Southern California Desert Retina Consultants, MC:
amd
non-exudative macular degeneration
exudative macular degeneration
 age-related macular degeneration
ranibizumab
anti-VEGF
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Ranibizumab
Angiogenesis Inhibitors
 Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents